NASDAQ:ANIX

Anixa Biosciences (ANIX) Stock Forecast, Price & News

$3.22

-0.06 (-1.83%)

(As of 05/26/2023 08:46 PM ET)

Compare

Today's Range: $3.17
▼
$3.45
50-Day Range: $3.22
▼
$5.97
52-Week Range: $2.77
▼
$6.45

Volume: 43,500 shs
Average Volume: 78,661 shs
Market Capitalization: $99.56 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.50

Anixa Biosciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 226.1% Upside
$10.50 Price Target
Short Interest: Bearish
2.12% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.43) to $2.08 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

727th out of 1,010 stocks

Pharmaceutical Preparations Industry

368th out of 494 stocks

3.5

Analyst's Opinion

Consensus Rating
Anixa Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.50, Anixa Biosciences has a forecasted upside of 226.1% from its current price of $3.22.
Amount of Analyst Coverage
Anixa Biosciences has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.12% of the float of Anixa Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Anixa Biosciences has a short interest ratio ("days to cover") of 6.3.
Change versus previous month
Short interest in Anixa Biosciences has recently increased by 4.24%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Anixa Biosciences does not currently pay a dividend.
Dividend Growth
Anixa Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ANIX.

1.7

News and Social Media Coverage

News Sentiment
Anixa Biosciences has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Anixa Biosciences this week, compared to 1 article on an average week.
Search Interest
Only 6 people have searched for ANIX on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
MarketBeat Follows
3 people have added Anixa Biosciences to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Anixa Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
20.40% of the stock of Anixa Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 11.21% of the stock of Anixa Biosciences is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Anixa Biosciences are expected to grow in the coming year, from ($0.43) to $2.08 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Anixa Biosciences is -7.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Anixa Biosciences is -7.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Anixa Biosciences has a P/B Ratio of 3.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Anixa Biosciences (NASDAQ:ANIX) Stock

Anixa Biosciences, Inc. is a biotechnology company, which engages in developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease. It operates through the following segments: CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics, Cancer Diagnostics, and Patent Licensing. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

Receive ANIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ANIX Stock News Headlines

May 23, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Anixa Biosciences

May 23, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Anixa Biosciences (ANIX)

May 29, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.

May 22, 2023 | finance.yahoo.com

Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial

April 25, 2023 | finance.yahoo.com

Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year?

April 19, 2023 | msn.com

Chardan Capital Reiterates Anixa Biosciences (ANIX) Buy Recommendation

April 19, 2023 | msn.com

HC Wainwright & Co. Reiterates Anixa Biosciences (ANIX) Buy Recommendation

April 18, 2023 | markets.businessinsider.com

Expert Ratings for Anixa Biosciences

May 29, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

April 18, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Anixa Biosciences (ANIX), Gamida Cell (GMDA) and Satsuma Pharmaceuticals (STSA)

April 17, 2023 | finance.yahoo.com

Anixa Biosciences Clarifies Poster Presentation on Company Website

April 17, 2023 | finance.yahoo.com

Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine

April 14, 2023 | nypost.com

Ohio woman, the first person to receive a breast cancer vaccine in trial, awaits results

April 14, 2023 | msn.com

Ohio woman, the first person to receive a breast cancer vaccine in trial, awaits results: 'Very excited'

April 14, 2023 | finance.yahoo.com

Here's What Could Help ANIXA BIOSCIENCES INC (ANIX) Maintain Its Recent Price Strength

April 13, 2023 | msn.com

Cleveland Clinic patient who received experimental breast cancer vaccine shares her story

April 4, 2023 | americanbankingnews.com

Short Interest in Anixa Biosciences, Inc. (NASDAQ:ANIX) Decreases By 5.6%

April 4, 2023 | americanbankingnews.com

Anixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Down 5.6% in March

March 29, 2023 | americanbankingnews.com

Anixa Biosciences, Inc. Forecasted to Post FY2023 Earnings of ($0.45) Per Share (NASDAQ:ANIX)

March 28, 2023 | americanbankingnews.com

Q2 2023 EPS Estimates for Anixa Biosciences, Inc. Lifted by HC Wainwright (NASDAQ:ANIX)

March 27, 2023 | finance.yahoo.com

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2023 AACR Annual Meeting

March 26, 2023 | americanbankingnews.com

Anixa Biosciences (NASDAQ:ANIX) Given New $12.00 Price Target at HC Wainwright

March 25, 2023 | americanbankingnews.com

Anixa Biosciences' (ANIX) "Buy" Rating Reiterated at Chardan Capital

March 24, 2023 | americanbankingnews.com

Research Analysts Issue Forecasts for Anixa Biosciences, Inc.'s Q1 2024 Earnings (NASDAQ:ANIX)

March 24, 2023 | americanbankingnews.com

Anixa Biosciences (NASDAQ:ANIX) Given New $9.00 Price Target at Chardan Capital

March 22, 2023 | markets.businessinsider.com

Chardan Capital Sticks to Its Buy Rating for Anixa Biosciences (ANIX)

March 17, 2023 | markets.businessinsider.com

Chardan Capital Sticks to Its Buy Rating for Immunome (IMNM)

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ANIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ANIX Company Calendar

Last Earnings: 3/16/2023
Today: 5/29/2023
Next Earnings (Estimated): 6/09/2023
Fiscal Year End: 10/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ANIX
CUSIP: N/A
CIK: 715446
Web: www.anixa.com
Phone: (408) 708-9808
Fax: 631-549-5974
Employees: 4
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.50
High Stock Price Forecast: $12.00
Low Stock Price Forecast: $9.00
Forecasted Upside/Downside: +226.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.41)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-13,600,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -41.18%
Return on Assets: -38.97%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 22.81
Quick Ratio: 22.81

Sales & Book Value

Annual Sales: $510,000.00
Price / Sales: 195.22
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.92 per share
Price / Book: 3.50

Miscellaneous

Outstanding Shares: 30,920,000
Free Float: 24,616,000
Market Cap: $99.56 million
Optionable: Not Optionable
Beta: 0.95

Key Executives

Amit D. Kumar
Executive Chairman & Chief Executive Officer

Michael J. Catelani
President, COO, CFO & Secretary

Pamela D. Garzone
Chief Development Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ANIX Stock - Frequently Asked Questions

Should I buy or sell Anixa Biosciences stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anixa Biosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANIX shares.
View ANIX analyst ratings or view top-rated stocks.
What is Anixa Biosciences' stock price forecast for 2023?: 2 equities research analysts have issued 12 month price objectives for Anixa Biosciences' stock. Their ANIX share price forecasts range from $9.00 to $12.00. On average, they predict the company's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 226.1% from the stock's current price.
View analysts price targets for ANIX or view top-rated stocks among Wall Street analysts.
How have ANIX shares performed in 2023?: Anixa Biosciences' stock was trading at $4.25 at the start of the year. Since then, ANIX stock has decreased by 24.2% and is now trading at $3.22.
View the best growth stocks for 2023 here.
When is Anixa Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, June 9th 2023.
View our ANIX earnings forecast.
How were Anixa Biosciences' earnings last quarter?: Anixa Biosciences, Inc. (NASDAQ:ANIX) released its earnings results on Thursday, March, 16th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.08.
What other stocks do shareholders of Anixa Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Anixa Biosciences investors own include Cronos Group (CRON), Innovative Industrial Properties (IIPR), Roku (ROKU), Ally Financial (ALLY), Albireo Pharma (ALBO), Air Lease (AL), Akoustis Technologies (AKTS), Akero Therapeutics (AKRO), Aimmune Therapeutics (AIMT) and Advanced Emissions Solutions (ADES).

What is Anixa Biosciences' stock symbol?: Anixa Biosciences trades on the NASDAQ under the ticker symbol "ANIX."
Who are Anixa Biosciences' major shareholders?: Anixa Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include UBS Group AG (2.07%), BlackRock Inc. (0.80%), Susquehanna International Group LLP (0.50%), Jane Street Group LLC (0.20%), Stifel Financial Corp (0.16%) and Renaissance Technologies LLC (0.07%). Insiders that own company stock include Amit Kumar, Arnold M Baskies, Emily Gottschalk, Lewis H Titterton Jr and Michael Catelani.
View institutional ownership trends.
How do I buy shares of Anixa Biosciences?: Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Anixa Biosciences' stock price today?: One share of ANIX stock can currently be purchased for approximately $3.22.
How much money does Anixa Biosciences make?: Anixa Biosciences (NASDAQ:ANIX) has a market capitalization of $99.56 million and generates $510,000.00 in revenue each year. The company earns $-13,600,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis.
How can I contact Anixa Biosciences?: Anixa Biosciences' mailing address is 3150 ALMADEN EXPRESSWAY SUITE 250, SAN JOSE CA, 95118. The official website for the company is www.anixa.com. The company can be reached via phone at (408) 708-9808, via email at mcatelani@ituscorp.com, or via fax at 631-549-5974.

This page (NASDAQ:ANIX) was last updated on 5/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial